Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GREGORY N FULLER and JASON HUSE.
GREGORY N FULLER
Connection Strength
1.412
JASON HUSE
  1. Collision tumor: Multinodular and vacuolating neuronal tumor with isocitrate dehydrogenase-mutant diffuse astrocytoma. Neuropathology. 2024 Feb 27.
    View in: PubMed
    Score: 0.244
  2. Coexisting FGFR3 p.K650T mutation in two FGFR3-TACC3 fusion glioma cases. Acta Neuropathol Commun. 2019 04 29; 7(1):63.
    View in: PubMed
    Score: 0.175
  3. FGFR1 tyrosine kinase domain duplication in pilocytic astrocytoma with anaplasia. Cold Spring Harb Mol Case Stud. 2018 04; 4(2).
    View in: PubMed
    Score: 0.162
  4. Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. Hum Pathol. 2017 11; 69:15-22.
    View in: PubMed
    Score: 0.153
  5. Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun. 2024 May 02; 15(1):3728.
    View in: PubMed
    Score: 0.062
  6. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad032.
    View in: PubMed
    Score: 0.057
  7. Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad026.
    View in: PubMed
    Score: 0.057
  8. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.054
  9. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
    View in: PubMed
    Score: 0.054
  10. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab079.
    View in: PubMed
    Score: 0.051
  11. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
    View in: PubMed
    Score: 0.048
  12. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
    View in: PubMed
    Score: 0.047
  13. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.047
  14. Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma. Nat Commun. 2019 07 18; 10(1):3170.
    View in: PubMed
    Score: 0.044
  15. RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report. Cancer Genet. 2019 02; 231-232:41-45.
    View in: PubMed
    Score: 0.043
  16. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
    View in: PubMed
    Score: 0.042
  17. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
    View in: PubMed
    Score: 0.040
  18. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.